Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

Precigen (PGEN) stock jumps as the FDA approves the company's gene therapy Papzimeos for adults with recurrent respiratory ...

Fintel reports that on August 15, 2025, JP Morgan upgraded their outlook for Precigen (NasdaqGS:PGEN) from Underweight to ...

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults ...

Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis (RRP), a rare ...

Evolv Technologies reported a quarterly loss of 2 cents per share which beat the analyst consensus estimate of a loss of 4 ...

Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

"With the landmark FDA approval of PAPZIMEOS and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," ...